Smarter leaders trust GlobalData

Data Insights Cell & gene therapy in pharma: lentiviral vectors

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Sanofi

Gilead Sciences Inc

Amgen Inc

Esteve Pharmaceuticals SA

Selecta Biosciences Inc

View all

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Lentiviral vectors is a key innovation area in cell & gene therapy

Lentiviral vectors are a type of viral vector used to deliver genetic material into cells. These vectors are derived from the human immunodeficiency virus (HIV) and can be modified to safely and efficiently deliver therapeutic genes to target cells. Lentiviral vectors are commonly used in gene therapy and are especially useful for targeting cells that are difficult to transfect using other methods.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 690 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of lentiviral vectors.

Key players in lentiviral vectors – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to lentiviral vectors

bluebird bio is one of the leading patent filers in lentiviral vectors. bluebird bio is a biotechnology company that focuses on the development and commercialization of gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as lentiviral gene addition platform, cancer immunotherapy, and gene editing. Its product pipeline includes elivaldogene autotemcel for the treatment of cerebral adrenoleukodystrophy (CALD), betibeglogene autotemcel for transfusion-dependent beta thalassemia, lovo-cel for the treatment of sickle cell disease, in addition to compounds under development for the treatment of various cancers. Sanofi and Takeda are some of the other key patent filers in lentiviral vectors.

In terms of application diversity, 2Seventy Bio leads the pack, while Amgen and Gilead Sciences stood in the second and third positions, respectively. By means of geographic reach, Selecta Biosciences held the top position, followed by Esteve Pharmaceuticals and C. H. Boehringer Sohn.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.